MedTrace Logo

A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

NCT07290036 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 392

Last updated 2026-05-22

No results posted yet for this study

Summary

To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.

Conditions

Interventions

DRUG

Bimekizumab regimen 1 iv

Participants will receive bimekizumab (BKZ) at pre-specified time points.

DRUG

Bimekizumab regimen 2 iv

Participants will receive bimekizumab (BKZ) at pre-specified time points.

DRUG

Bimekizumab regimen 3 sc

Participants will receive bimekizumab (BKZ) at pre-specified time points.

Sponsors & Collaborators

  • UCB Biopharma SRL

    lead INDUSTRY

Principal Investigators

  • UCB Cares · 001 844 599 22733 (UCB)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-10
Primary Completion
2028-05-18
Completion
2028-09-14
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Czechia
  • Germany
  • Poland
  • Slovakia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07290036 on ClinicalTrials.gov